Three drug discovery projects have been named recipients of the 2018 Biomedical Innovation Program awards. The awards program is a collaboration of the Oregon Clinical and Translational Research Institute and Technology Transfer and Business Development.
The awards provide funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace. This track of funding supports drug discovery platforms and early stage therapeutic technology projects.
2018 BIP Drug Discovery awardees and project abstracts:
- Martin Kelly, Ph.D., professor of physiology and pharmacology, School of Medicine
Novel Alzheimer’s Disease Drugs and their Target - Stephen Lloyd, Ph.D., professor, Oregon Institute of Occupational Health Sciences, Department of Molecular and Medical Genetics, School of Medicine
Development of Agonists for the Prevention of Obesity and Obesity-related Diseases - Arthur Vandenbark, Ph.D., professor of neurology and molecular microbiology and immunology, School of Medicine, senior research scientist, Portland VA Medical Center
Novel CD74 Decoy Peptides for Treatment of Progressive Multiple Sclerosis
By prioritizing commercialization outcomes, the BIP helps position technologies to have the best possible chance of making it to market and improving human health.
Detailed information on the awards is available on the OCTRI website. For information on other OCTRI’s other research support services, visit http://www.ohsu.edu/octri
OCTRI and the BIP are supported by (UL1TR002369) from the National Center for Advancing Translational Science (NCATS) at the National Institutes of Health (NIH).
Additional funding for the BIP is made possible by the University Venture Development Fund (UVDF). You may contact Timothy Coffey at coffeyt@ohsu.edu for information on the fund.
